Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Alderson

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
International Journal of Pediatric Otorhinolaryngology|January 18, 2020
Panel 8: Vaccines and immunologyMark R Alderson, Tim Murphy, Stephen I Pelton, et al.
Infection and Immunity|December 23, 2003
Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test designJohan Vekemans, Martin O C Ota, Jackson Sillah, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|April 5, 2017
Panel 6: VaccinesMelinda M Pettigrew, Mark R Alderson, Lauren O Bakaletz, et al.
Vaccine|December 27, 2016
WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016Miwako Kobayashi, Stephanie J Schrag, Mark R Alderson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2004
Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant proteinYasir A W Skeiky, Mark R Alderson, Pamela J Ovendale, et al.
Elife|December 29, 2018
Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccinationJoseph J Campo, Timothy Q Le, Jozelyn V Pablo, et al.
Vaccine|December 18, 2019
Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trialEd Clarke, Adedapo O Bashorun, Michael Okoye, et al.
Vaccine|February 6, 2018
Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristicsJohan Vekemans, Vasee Moorthy, Martin Friede, et al.
Infection and Immunity|October 27, 2004
The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigsLise Brandt, Yasir A W Skeiky, Mark R Alderson, et al.
The Lancet. Infectious Diseases|January 13, 2023
Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trialIkechukwu Adigweme, Ahmed Futa, Ebrima Saidy-Jah, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
International Journal of Pediatric Otorhinolaryngology|January 18, 2020
Panel 8: Vaccines and immunologyMark R Alderson, Tim Murphy, Stephen I Pelton, et al.
Infection and Immunity|December 23, 2003
Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test designJohan Vekemans, Martin O C Ota, Jackson Sillah, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|April 5, 2017
Panel 6: VaccinesMelinda M Pettigrew, Mark R Alderson, Lauren O Bakaletz, et al.
Vaccine|December 27, 2016
WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016Miwako Kobayashi, Stephanie J Schrag, Mark R Alderson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2004
Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant proteinYasir A W Skeiky, Mark R Alderson, Pamela J Ovendale, et al.
Elife|December 29, 2018
Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccinationJoseph J Campo, Timothy Q Le, Jozelyn V Pablo, et al.
Vaccine|December 18, 2019
Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trialEd Clarke, Adedapo O Bashorun, Michael Okoye, et al.
Vaccine|February 6, 2018
Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristicsJohan Vekemans, Vasee Moorthy, Martin Friede, et al.
Infection and Immunity|October 27, 2004
The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigsLise Brandt, Yasir A W Skeiky, Mark R Alderson, et al.
The Lancet. Infectious Diseases|January 13, 2023
Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trialIkechukwu Adigweme, Ahmed Futa, Ebrima Saidy-Jah, et al.
Pageof 4